The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
Conclusion: The analysis described here illustrates the broader public economic benefits for government attributed to changes in disease status. The lifetime social insurance transfer costs were highest in non-treated patients, and lower social insurance costs were demonstrated with DMTs. These findings suggest that focusing cost-effectiveness analysis only on health costs will likely underestimate the value of DMTs.
PMID: 32400258 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 15, 2020 Category: Health Management Tags: J Med Econ Source Type: research
Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
Conclusions
sNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS. It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS. This study provides Class III evidence that sNfL levels are associated with disease activity in pediatric MS. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - May 12, 2020 Category: Neurology Authors: Reinert, M.-C., Benkert, P., Wuerfel, J., Michalak, Z., Ruberte, E., Barro, C., Huppke, P., Stark, W., Kropshofer, H., Tomic, D., Leppert, D., Kuhle, J., Brück, W., Gärtner, J. Tags: All Pediatric, Multiple sclerosis Article Source Type: research
Corrigendum to “Subcutaneous interferon beta-1a 22/44 µg demonstrates comparable effectiveness versus teriflunomide in newly treated patients with multiple sclerosis. A study in a French nationwide cohort of Multiple Sclerosis: Observatoire Francais de la sclérose en plaques” [Multiple Sclerosis and Related Disorders, 37 (2020) 101598]
Publication date: Available online 18 April 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Fabien Rollot, Caroline Foch, David Laplaud, Emmanuelle Boutmy, Kurt Marhardt, Meritxell Sabidó (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 18, 2020 Category: Neurology Source Type: research
Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients
ConclusionOur longitudinal pilot study confirms that sNfL are related to cognitive abilities, confirming data of other authors from retrospective studies. (Source: Journal of Neurology)
Source: Journal of Neurology - April 14, 2020 Category: Neurology Source Type: research
Monitoring of radiologic disease activity by serum neurofilaments in MS
Conclusions
Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of recent radiologic disease activity during the preceding year. This result suggests that in future, sNfL assessment may substitute the need for annual brain MRI monitoring in considerable number (23.1%–36.4%) of visits in clinically stable patients. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - April 8, 2020 Category: Neurology Authors: Uher, T., Schaedelin, S., Srpova, B., Barro, C., Bergsland, N., Dwyer, M., Tyblova, M., Vodehnalova, K., Benkert, P., Oechtering, J., Leppert, D., Naegelin, Y., Krasensky, J., Vaneckova, M., Kubala Havrdova, E., Kappos, L., Zivadinov, R., Horakova, D., Ku Tags: MRI, Multiple sclerosis Article Source Type: research
Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
Conclusions. EXPAND provides evidence of the efficacy of siponimod compared with placebo, and these MAIC complement this by demonstrating improved efficacy of siponimod relative to DMTs. Siponimod offers a significant therapeutic advance that may slow disease progression compared to other DMTs in an EXPAND-like population with secondary progressive disease.
PMID: 32220214 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 31, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study
ConclusionIFN- β1a evening injections in the first 8 weeks of treatment led to an improvement in FLS; when continuing therapy, time of administration could be decided according to patient’s lifestyle and preference. (Source: Journal of Neurology)
Source: Journal of Neurology - March 4, 2020 Category: Neurology Source Type: research
Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review.
CONCLUSIONS: The present paper shows that cost-effectiveness studies have high levels of methodological variability, some of them reaching contradictory results. As a result, it is not possible to determine which disease- modifying therapy is really cost-effective in the context of relapsingremitting multiple sclerosis.
PMID: 32452318 [PubMed - in process] (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 29, 2020 Category: Drugs & Pharmacology Authors: Navarro CE, Ordóñez-Callamand E, Alzate JP Tags: Farm Hosp Source Type: research
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr é syndrome.
CONCLUSIONS: All six RCTs were too small to exclude clinically important benefit or harm from the assessed interventions. The certainty of the evidence was low or very low for all interventions and outcomes.
PMID: 31981368 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - January 24, 2020 Category: General Medicine Authors: Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J Tags: Cochrane Database Syst Rev Source Type: research
Interferon beta-1a induces expression of brain-derived neurotrophic factor in human T lymphocytes in vitro and not in vivo
Future Neurology, Ahead of Print. (Source: Future Neurology)
Source: Future Neurology - January 13, 2020 Category: Neurology Authors: Zarlascht Karmand Hans-Peter Hartung Oliver Neuhaus Source Type: research
Relapse recovery: The forgotten variable in multiple sclerosis clinical trials
Conclusions
In patients with MS presenting without good recovery after the initial relapse, immediate DMT initiation favorably influences the likelihood of more ambulatory-benign disease akin to patients with good recovery after the initial relapse.
Classification of evidence
This study provides Class III evidence that for patients with MS without good recovery after the initial relapse, immediate DMT initiation increases the likelihood of a benign disease course. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - December 16, 2019 Category: Neurology Authors: Kantarci, O. H., Zeydan, B., Atkinson, E. J., Conway, B. L., Castrillo-Viguera, C., Rodriguez, M. Tags: Quality of life, Class III, Burden of disease, Multiple sclerosis Article Source Type: research
Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany
ConclusionAmong the four MS subtypes, RRMS patients most often received a disease-modifying immunomodulatory treatment. Consequently, healthcare costs were highest for patients with this MS subtype. Contrary to the treatment guideline, a substantial percentage of patients with CIS, RRMS, and SPMS did not receive any disease-modifying immunomodulatory treatment. (Source: Neurology and Therapy)
Source: Neurology and Therapy - December 11, 2019 Category: Neurology Source Type: research
M104 interference of interferon beta-1a with venom immunotherapy in a patient with multiple sclerosis
We present a patient where interferon-beta1a (IFN β1a) appears to amplify adverse effects of venom immunotherapy (VIT) and diminish desensitization. IFNβ1a is a disease modifying therapy for relapsing/remitting multiple sclerosis (MS). Her case is further complicated by her high sting risk occupation and living in a rural setting requiring helico pter transport for medical care. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: A. Chau, D. Petroni Source Type: research
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Conclusions
Repopulation kinetics of the evaluated peripheral lymphocyte subsets did not predict autoimmune AE occurrence or disease activity, including return of disease activity after 2 alemtuzumab courses. Further study is needed to investigate potential antigen-level markers of treatment response. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - October 28, 2019 Category: Neurology Authors: Wiendl, H., Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N., Chung, L., Jacobs, A. K., Hogan, R. J., Wychowski, L. V., Van Wijmeersch, B., On behalf of the CARE-MS I, CARE-MS II, and CAMMS03409 Investigators Tags: MRI, Autoimmune diseases, Clinical trials Randomized controlled (CONSORT agreement), Multiple sclerosis Article Source Type: research
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
ConclusionsAlemtuzumab was efficacious in a small cohort of relapsing-remitting MS patients of African descent over 8 years. Safety was consistent with the overall CARE-MS population, although the small sample size may have prevented the detection of known low-frequency adverse events.ClinicalTrials.gov Registration NumbersCARE-MS I, II, extension, TOPAZ: NCT00530348, NCT00548405, NCT00930553, NCT02255656.FundingSanofi (Cambridge, MA, USA) and Bayer HealthCare Pharmaceuticals (Leverkusen, Germany). (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 24, 2019 Category: Neurology Source Type: research
